vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and Verisign (VRSN). Click either name above to swap in a different company.

CLOVER HEALTH INVESTMENTS, CORP. is the larger business by last-quarter revenue ($487.7M vs $425.3M, roughly 1.1× Verisign). Verisign runs the higher net margin — 48.5% vs -10.1%, a 58.6% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (44.7% vs 7.6%). Verisign produced more free cash flow last quarter ($285.1M vs $-69.0M). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (18.6% CAGR vs 5.2%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

Verisign, Inc. is an American company based in Reston, Virginia, that operates a diverse array of network infrastructure, including two of the Internet's thirteen root nameservers, the authoritative registry for the .com, .net, and .name generic top-level domains and the .cc country-code top-level domains, and the back-end systems for the .jobs and .edu sponsored top-level domains.

CLOV vs VRSN — Head-to-Head

Bigger by revenue
CLOV
CLOV
1.1× larger
CLOV
$487.7M
$425.3M
VRSN
Growing faster (revenue YoY)
CLOV
CLOV
+37.2% gap
CLOV
44.7%
7.6%
VRSN
Higher net margin
VRSN
VRSN
58.6% more per $
VRSN
48.5%
-10.1%
CLOV
More free cash flow
VRSN
VRSN
$354.1M more FCF
VRSN
$285.1M
$-69.0M
CLOV
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
18.6%
5.2%
VRSN

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CLOV
CLOV
VRSN
VRSN
Revenue
$487.7M
$425.3M
Net Profit
$-49.3M
$206.2M
Gross Margin
88.5%
Operating Margin
-10.1%
67.0%
Net Margin
-10.1%
48.5%
Revenue YoY
44.7%
7.6%
Net Profit YoY
-123.2%
7.7%
EPS (diluted)

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
VRSN
VRSN
Q4 25
$487.7M
$425.3M
Q3 25
$496.6M
$419.1M
Q2 25
$477.6M
$409.9M
Q1 25
$462.3M
$402.3M
Q4 24
$337.0M
$395.4M
Q3 24
$331.0M
$390.6M
Q2 24
$356.3M
$387.1M
Q1 24
$346.9M
$384.3M
Net Profit
CLOV
CLOV
VRSN
VRSN
Q4 25
$-49.3M
$206.2M
Q3 25
$-24.4M
$212.8M
Q2 25
$-10.6M
$207.4M
Q1 25
$-1.3M
$199.3M
Q4 24
$-22.1M
$191.5M
Q3 24
$-9.2M
$201.3M
Q2 24
$7.4M
$198.8M
Q1 24
$-19.2M
$194.1M
Gross Margin
CLOV
CLOV
VRSN
VRSN
Q4 25
88.5%
Q3 25
88.4%
Q2 25
88.0%
Q1 25
87.7%
Q4 24
87.8%
Q3 24
24.5%
88.0%
Q2 24
30.3%
87.8%
Q1 24
23.6%
87.2%
Operating Margin
CLOV
CLOV
VRSN
VRSN
Q4 25
-10.1%
67.0%
Q3 25
-4.9%
67.8%
Q2 25
-2.2%
68.5%
Q1 25
-0.3%
67.4%
Q4 24
-6.4%
66.7%
Q3 24
-2.7%
68.9%
Q2 24
2.0%
68.8%
Q1 24
-6.5%
67.4%
Net Margin
CLOV
CLOV
VRSN
VRSN
Q4 25
-10.1%
48.5%
Q3 25
-4.9%
50.8%
Q2 25
-2.2%
50.6%
Q1 25
-0.3%
49.5%
Q4 24
-6.6%
48.4%
Q3 24
-2.8%
51.5%
Q2 24
2.1%
51.4%
Q1 24
-5.5%
50.5%

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
VRSN
VRSN
Cash + ST InvestmentsLiquidity on hand
$78.3M
$580.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$308.7M
$-2.2B
Total Assets
$541.0M
$1.3B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
VRSN
VRSN
Q4 25
$78.3M
$580.5M
Q3 25
$617.7M
Q2 25
$593.8M
Q1 25
$648.5M
Q4 24
$194.5M
$599.9M
Q3 24
$288.0M
$644.9M
Q2 24
$254.8M
$689.9M
Q1 24
$208.3M
$924.7M
Stockholders' Equity
CLOV
CLOV
VRSN
VRSN
Q4 25
$308.7M
$-2.2B
Q3 25
$340.9M
$-2.1B
Q2 25
$344.2M
$-2.0B
Q1 25
$336.1M
$-2.0B
Q4 24
$341.1M
$-2.0B
Q3 24
$342.2M
$-1.9B
Q2 24
$324.9M
$-1.8B
Q1 24
$292.5M
$-1.6B
Total Assets
CLOV
CLOV
VRSN
VRSN
Q4 25
$541.0M
$1.3B
Q3 25
$559.7M
$1.4B
Q2 25
$575.0M
$1.4B
Q1 25
$583.7M
$1.4B
Q4 24
$580.7M
$1.4B
Q3 24
$653.0M
$1.5B
Q2 24
$674.2M
$1.5B
Q1 24
$671.8M
$1.7B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
VRSN
VRSN
Operating Cash FlowLast quarter
$-66.9M
$289.6M
Free Cash FlowOCF − Capex
$-69.0M
$285.1M
FCF MarginFCF / Revenue
-14.1%
67.0%
Capex IntensityCapex / Revenue
0.4%
1.1%
Cash ConversionOCF / Net Profit
1.40×
TTM Free Cash FlowTrailing 4 quarters
$-69.2M
$1.1B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
VRSN
VRSN
Q4 25
$-66.9M
$289.6M
Q3 25
$12.1M
$307.7M
Q2 25
$5.4M
$202.5M
Q1 25
$-16.3M
$291.3M
Q4 24
$34.8M
$231.5M
Q3 24
$50.0M
$253.4M
Q2 24
$44.8M
$160.4M
Q1 24
$25.9M
$257.3M
Free Cash Flow
CLOV
CLOV
VRSN
VRSN
Q4 25
$-69.0M
$285.1M
Q3 25
$11.4M
$303.0M
Q2 25
$4.8M
$194.7M
Q1 25
$-16.5M
$285.5M
Q4 24
$33.3M
$222.0M
Q3 24
$49.6M
$247.8M
Q2 24
$44.4M
$151.2M
Q1 24
$25.5M
$253.5M
FCF Margin
CLOV
CLOV
VRSN
VRSN
Q4 25
-14.1%
67.0%
Q3 25
2.3%
72.3%
Q2 25
1.0%
47.5%
Q1 25
-3.6%
71.0%
Q4 24
9.9%
56.1%
Q3 24
15.0%
63.4%
Q2 24
12.5%
39.1%
Q1 24
7.3%
66.0%
Capex Intensity
CLOV
CLOV
VRSN
VRSN
Q4 25
0.4%
1.1%
Q3 25
0.1%
1.1%
Q2 25
0.1%
1.9%
Q1 25
0.0%
1.4%
Q4 24
0.5%
2.4%
Q3 24
0.1%
1.4%
Q2 24
0.1%
2.4%
Q1 24
0.1%
1.0%
Cash Conversion
CLOV
CLOV
VRSN
VRSN
Q4 25
1.40×
Q3 25
1.45×
Q2 25
0.98×
Q1 25
1.46×
Q4 24
1.21×
Q3 24
1.26×
Q2 24
6.04×
0.81×
Q1 24
1.33×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons